Stock Analysis of Aerovate Therapeutics Inc (AVTE) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code AVTE
Close 20.57
Change -1.34 / 6.12 %
Volume 136803
Vol Change -115271.00 / 45.73 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Aerovate Therapeutics Inc
PE (TTM)

-6.93

Very Poor
Price / Book

4.90

Very Poor
Price / Sales

4187.08

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

592586 K

Enterprise Value

569515 K

ROA (TTM)

-62.71

Very Poor
ROE (TTM)

-70.72

Very Poor
Net Margin (TTM)

-60431.62

Very Poor
Revenue

%

0
Net Profit

36.15 %

-70130.00 K
Debt to Equity

0.0038

Excellent
Altman Z Score

17.19

Excellent
Quick Ratio

0

Poor
Cash Ratio

6.94

Excellent


Highs/Lows of Aerovate Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week19.83 3.73 % 1.54 % 22.4818.3716-May-2414-May-24
Two Week20.29 1.38 % 3.42 % 22.4818.3716-May-2414-May-24
One Month22.5 8.58 % 5.60 % 23.976418.3724-Apr-2414-May-24
Three Month20.91 1.63 % 5.95 % 32.41518.0401-Apr-2420-Feb-24
Six Months14.49 41.96 % 17.48 % 32.41514.0901-Apr-2420-Nov-23
One year19.46 5.70 % 27.52 % 32.4159.4101-Apr-2430-Oct-23
Two year12.25 67.92 % 29.70 % 32.4159.4101-Apr-2430-Oct-23


Technical View of Aerovate Therapeutics Inc
RSI

44.86

Neutral
MACD

-0.899

Mild Bullish
ADX

13.94

Bullish
Super Trend

24.27

Mild Bearish
Williams %R

-46.47

Strong Bearish
CCI

-2.17

Neutral


EMA 5

20.72

Bearish
EMA 15

20.95

Neutral
EMA 50

22.34

Mild Bearish
EMA 100

21.65

Whipsaw
SMA 100

22.35

Strong Bearish
SMA 200

18.28

Bullish
SMA 5 / 20

20.38 / 20.89

Mild Bearish
SMA 15 / 50

20.52 / 24.08

Strong Bearish
SMA 50 / 200

24.08 / 18.28

Strong Bullish




Charts of Aerovate Therapeutics Inc


Returns of Aerovate Therapeutics Inc with Peers
Period / StockAVTECALTHROWMNMD
1 Week3.73%8.03%44.48%-11.23%
1 Mth-8.58%18.41%41.79%-13.75%
3 Mth-1.63%4.47%57.08%67.07%
6mth41.96%28.34%87.05%217.37%
1 Year5.70%5.22%-22.44%160.95%
2 Year67.92%45.99%189.97%-29.24%
5 Years--174.30%795.42%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aerovate Therapeutics Inc with Peers
Ratio / StockAVTECALTHROWMNMD
PE-6.93-3.01-18.11-1285.38
P/B4.901.9511.391327.98
ROA-62.71-16.52-11.74-74.66
ROE-70.72-64.78-62.43-103.31
Debt To Equity0.00382.842.610.181
Revenue0
% 		1184.37 M
47.52 % 		114167 K
28.86 % 		0
%
Net Income-70130.00 K
36.15 % 		-451498.00 K
9.52 % 		-14208.00 K
0.866 % 		-76771.00 K
35.17 %


Technicals of Aerovate Therapeutics Inc with Peers
Technical / StockAVTECALTHROWMNMD-
ADX13.9414.6331.1417.81
CMF0.0650.1280.02040.075
MFI60.5072.3482.5045.39
RSI44.8661.2877.6541.61
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MAFalseTrueTrueFalse-
Price Above 200 MATrueTrueTrueTrue-


About : Aerovate Therapeutics Inc

Address : 930 Winter Street, Waltham, MA, United States, 02451
Tel : 617 443 2400
URL : https://aerovatetx.com
Code : AVTE, ISIN : US0080641071, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 30_Jun_2021
Employee Count : 51

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)